Loader

Pathways

PathWhiz ID Pathway Meta Data

PW126600

Pw126600 View Pathway
metabolic

Cannabinoid Biosynthesis

Cannabis sativa
Hexanoate is first catalyzed to make hexanoyl-CoA with the enzyme hexanoyl CoA synthase in the cytosol and within the membrane of the cell. Hexanoyl-CoA branches paths to olivetol biosynthesis which creates the byproducts of this pathway. The other pathway is catalyzed by olivetol synthase to make 3,5-dioxodecanoyl-CoA which is catalyzed to make 3,5,7-trioxododecanoyl-CoA. This is similar to the olivetol biosynthesis pathway, however here 3,5,7-trioxododecanoyl-CoA is catalyzed by olivetolic acid cyclase to make olivetolate. This takes place in the cytoplasm. Olivetolate along with geranyl diphosphate is catalyzed by olivetolate geranyltransferase to make cannabigerolate or cannabigerolic acid. This compound branches into three separate pathways each catalyzed by a different enzymes. One pathway is catalyzed by Δ9-tetrahydrocannabinolate synthase along with oxygen to make Δ9-tetrahydrocannabinolate. This compound spontaneously reacts with hydrogen to synthesize the drug Δ9-tetrahydrocannabinol (THC). The second pathway is catalyzed by cannabidiolate synthase and oxygen to make cannabidiolate or cannabidiolic acid. Cannabidiolate spontaneously reacts with hydrogen to synthesize the drug cannabidiol (CBD). The final pathway is catalyzed by cannabichromenate synthase along with an unknown oxidized electron carrier to make cannabichromenate or cannabichromenic acid. This, like the others, spontaneously reacts with hydrogen to synthesize the drug cannabichromene (CBC).

PW145945

Pw145945 View Pathway
drug action

Cannabidiol Drug Metabolism Action Pathway

Homo sapiens

PW124429

Pw124429 View Pathway
metabolic

Cannabidiol and delta9-THC Biosynthesis

Cannabis sativa

PW145715

Pw145715 View Pathway
drug action

Cangrelor Drug Metabolism Action Pathway

Homo sapiens

PW132563

Pw132563 View Pathway
metabolic

Cangrelor Drug Metabolism

Homo sapiens
Cangrelor is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Cangrelor passes through the liver and is then excreted from the body mainly through the kidney.

PW122421

Pw122421 View Pathway
drug action

Cangrelor Action Pathway

Homo sapiens
Cangrelor, marketed as Kengreal or Kengrexal, is an antiplatelet drug that targets the P2Y12 receptor of platelets. It was developed as a derivative of ATP that is not enzymatically degraded by the cell. Cangrelor is already active, and is injected intravenously. Here, it binds to the P2Y purinoreceptor 12 on the surface of platelet cells, preventing ADP from binding to and activating it. Cangrelor prevents the activation of the Gi protein associated with the P2Y12 receptor from inactivating adenylate cyclase in the platelet, leading to a buildup of cAMP. This cAMP then activates calcium efflux pumps, preventing calcium buildup in the platelet, which would cause activation, and later, aggregation.

PW127405

Pw127405 View Pathway
drug action

Candoxatril

Homo sapiens
Candoxatril is the prodrug of candoxatrilat that is activated via oral consumption, it is also a neutral endopeptidase inhibitor. It inhibits the metalloprotease enzymes, neutral endopeptidase and angiotensin-converting enzyme; inhibiting these enzymes increases peptides that act to induce vasodilation.

PW145240

Pw145240 View Pathway
drug action

Candicidin Drug Metabolism Action Pathway

Homo sapiens

PW127403

Pw127403 View Pathway
drug action

Candicidin Action Pathway

Homo sapiens
Candicidin is a polyene antifungal antibiotic produced by a strain of Streptomyces griseus. It is especially effective against Candida albicans (more effective than amphotericin B), and is administered intravaginally in the treatment of vulvovaginal candidiasis. Ergosterol, the principal sterol in the fungal cytoplasmic membrane, is the target site of action of Candicidin. Candicidin binds irreversibly to ergosterol, resulting in disruption of membrane integrity and ultimately cell death.

PW175988

Pw175988 View Pathway
metabolic

Candesartan cilexetil Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Candesartan cilexetil are predicted with biotransformer.